DDrare: Database of Drug Development for Rare Diseases

Searched query = "IgG4-related disease", "Autoimmune pancreatitis", "IgG4-related sclerosing cholangitis", "IgG4-related lacrimal gland, orbital, and salivary gland lesions", "IgG4-related kidney disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 18F-FDG; 68Ga-FAPI; Abatacept; Afucosylated IgG1 kappa monoclonal antibody; Belimumab; Corticosteroids; Device: Mayo Interactive Breath Hold Monitor; Drug free, IS monotherapy and GC combined with IS; Extra blood draw samples; Glucocorticoids; INEBILIZUMAB; Inebilizumab; Leflunomide; Lenalidomide; MONITOR; Methionine; Mycophenolate; Mycophenolate mofetil; Perflubutane; Prednisolone; Prednisone; Prednisone and Belimumab; Prednisone and Mycophenolate mofetil; Procedure: biliary stent; Rilzabrutinib; Rituximab; T 614; Thalidomide; XMAB5871; XmAb5871; Zanubrutinib; Zanubrutinib 80 MG; [XmAb5871]

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02703194 (ClinicalTrials.gov)	March 2016	27/2/2016	Leflunomide for Maintenance of Remission in IgG4 Related Disease	A Study of Safety and Efficacy of Leflunomide for Maintenance of Remission in IgG4 Related Disease	Immunoglobulin G4 Related Sclerosing Disease	Drug: Prednisone;Drug: Leflunomide	Chinese PLA General Hospital	NULL	Completed	18 Years	80 Years	All	68	Phase 4	China

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02703194
(ClinicalTrials.gov)

March 2016

27/2/2016

Leflunomide for Maintenance of Remission in IgG4 Related Disease

A Study of Safety and Efficacy of Leflunomide for Maintenance of Remission in IgG4 Related Disease

Immunoglobulin G4 Related Sclerosing Disease

Drug: Prednisone;Drug: Leflunomide

Chinese PLA General Hospital

NULL

Completed

18 Years

80 Years

All

Phase 4

China